Last reviewed · How we verify
XW003
XW003 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
XW003 is a small molecule inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.
At a glance
| Generic name | XW003 |
|---|---|
| Also known as | GLP-1 analogue, ecnoglutide |
| Sponsor | Sciwind Biosciences APAC CO Pty. Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, XW003 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is thought to contribute to its therapeutic effects in treating type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy (PHASE3)
- A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy (PHASE3)
- A Study of XW003 Injection in Chinese Adolescents With Obesity (PHASE1)
- A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients (PHASE3)
- A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH) (PHASE2)
- A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM (PHASE3)
- A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin (PHASE1)
- A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XW003 CI brief — competitive landscape report
- XW003 updates RSS · CI watch RSS
- Sciwind Biosciences APAC CO Pty. Ltd. portfolio CI